Medpace Holdings is a global clinical research organization that provides comprehensive drug development services to the pharmaceutical and biotechnology industries. Its core offerings include clinical trial management, regulatory consulting, and data management. The company operates primarily in the healthcare sector, focusing on therapeutic areas such as oncology, cardiology, and infectious diseases. Major revenue sources stem from service contracts with clients in the life sciences sector.
The investment profile of Medpace Holdings is more aligned with balanced investors, given its stable revenue generation and growth potential in the healthcare sector. The absence of dividends suggests a focus on reinvestment rather than income generation. The stock may appeal to those seeking moderate growth with a reasonable risk profile.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-25 | Hold | Buy | Strong momentum and solid fundamentals support growth potential. |
| 2026-07-23 | — | Hold | Mixed performance; cautious due to high risk factors. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-07-24 | RBC Capital | Target Raised | 484 → 692 | 601.73 |
| 2026-07-24 | Mizuho Securities | Target Raised | 586 → 665 | 605.82 |
| 2026-07-24 | BMO Capital | Target Raised | 400 → 600 | 605.82 |
| 2026-07-24 | Robert W. Baird | Target Raised | 547 → 624 | 605.82 |
| 2026-07-23 | Barclays | Target Raised | 450 → 600 | 605.82 |
| 2026-07-23 | Leerink Partners | Target Raised | 515 → 620 | 605.82 |
| 2026-07-23 | Deutsche Bank | Target Raised | 480 → 535 | 602.995 |
| 2026-07-13 | Mizuho Securities | Target Raised | 495 → 586 | 538.23 |
| 2026-07-08 | Robert W. Baird | Rating Downgraded | — → 547 | 546.29 |
| 2026-07-07 | Jefferies | Update | — → 515 | 565.09 |
| 2026-04-24 | BMO Capital | Target Lowered | 460 → 400 | 402.806 |
| 2026-04-24 | RBC Capital | Target Lowered | 522 → 484 | 393.42 |
| 2026-04-24 | Robert W. Baird | Target Lowered | 565 → 477 | 393.42 |
| 2026-04-24 | Barclays | Target Lowered | 500 → 450 | 393.42 |
| 2026-03-06 | Barclays | Update | — → 500 | 468.355 |
| 2026-02-13 | Jefferies | Rating Upgraded | — → 560 | 416.04 |
| 2026-02-11 | Truist Financial | Target Lowered | 555 → 539 | 431.165 |
